Abstract
Background: The characterization of reinfection with SARS-CoV-2 has been a subject of concern and controversy, especially with the surge of infections with highly transmissible variants worldwide.
Methods: This retrospective national study used comorbidities, vaccination status, SARS-CoV-2 variants of concern, and demographics data to profile participants who were reinfected with SARS-CoV-2, defined as having two reverse transcriptase-polymerase chain reaction-positive SARS-CoV-2 tests within at least 90 days apart. A multivariate logistic regression model assessed the risk factors associated with reinfection . Two control groups were selected: nonreinfected participants reporting a positive test (control group one) and those reporting a negative test (control group two).
Results: Between March 2020 and December 2021, 4454 reinfected participants were identified in Saudi Arabia (0.8%, 95% confidence interval [CI] 0.7-0.8). The majority (67.3%) were unvaccinated (95% CI 65.9-68.7) and 0.8% (95% CI 0.6-1.1) had severe or fatal SARS-CoV-2 disease. COVID-19 vaccines were 100% effective against mortality in reinfected individuals who received at least one dose, whereas it conferred 61% (odds ratio [OR] 0.4, 95% CI 0.1-1.0) additional protection against severe disease after the first dose and 100% after the second dose. In the risk factor analysis, reinfection was highly associated with comorbidities, such as HIV (OR 2.5, 95% CI 1.3-5.2; P = 0.009), obesity (OR 2.3, 95% CI 1.3-3.9; P = 0.003), pregnancy (OR 3.2, 95% CI 1.4-7.4; P = 0.005), and working in health care facilities (OR 6.1, 95% CI 3.1-12.9; P <0.0001). The delta variant (B.1.617.2) was the most frequent variant of concern among the reinfected cohort.
Conclusion: This in-depth study of the reinfection profile identified risk factors and highlighted the associated SARS-CoV-2 variants. Results showed that naturally acquired immunity to SARS-CoV-2 through multiple reinfections together with vaccine-induced immunity provided substantial protection against severe SARS-CoV-2 disease and mortality.
Keywords: Protective Immunity; Risk Factor; SARS-CoV-2 Reinfection; Saudi Arabia; Vaccination; Variant Of Concern.
【저자키워드】 vaccination, risk factor, Saudi Arabia, protective immunity, Variant of concern., SARS-CoV-2 reinfection, 【초록키워드】 SARS-CoV-2, HIV, COVID-19 vaccine, Mortality, obesity, variant, SARS-CoV-2 variant, Infection, Comorbidities, B.1.617.2, Reinfection, Cohort, Pregnancy, Health, SARS-CoV-2 variants, concern, disease, Care, retrospective, Analysis, dose, Odds ratio, naturally acquired immunity, severe disease, Vaccine-induced immunity, demographics, SARS-CoV-2 disease, control group, 95% CI, 95% confidence interval, subject, second dose, first dose, individual, multivariate logistic regression, participant, Positive test, National, SARS-CoV-2 test, negative test, effective, severe SARS-CoV-2, Result, defined, provided, majority, transmissible variant, 【제목키워드】 SARS-CoV-2, Rate,